- Home
- LCW vs IPHA Comparison
LCW vs IPHA Comparison
Compare LCW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCW
- IPHA
- Stock Information
- Founded
- LCW 2021
- IPHA 1999
- Country
- LCW United States
- IPHA France
- Employees
- LCW N/A
- IPHA N/A
- Industry
- LCW Blank Checks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- LCW Finance
- IPHA Health Care
- Exchange
- LCW Nasdaq
- IPHA Nasdaq
- Market Cap
- LCW 165.8M
- IPHA 191.0M
- IPO Year
- LCW 2021
- IPHA 2019
- Fundamental
- Price
- LCW $10.99
- IPHA $2.28
- Analyst Decision
- LCW
- IPHA Strong Buy
- Analyst Count
- LCW 0
- IPHA 1
- Target Price
- LCW N/A
- IPHA $11.50
- AVG Volume (30 Days)
- LCW 55.0K
- IPHA 5.5K
- Earning Date
- LCW 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- LCW N/A
- IPHA N/A
- EPS Growth
- LCW N/A
- IPHA N/A
- EPS
- LCW N/A
- IPHA N/A
- Revenue
- LCW N/A
- IPHA $36,202,722.00
- Revenue This Year
- LCW N/A
- IPHA N/A
- Revenue Next Year
- LCW N/A
- IPHA $105.84
- P/E Ratio
- LCW N/A
- IPHA N/A
- Revenue Growth
- LCW N/A
- IPHA 6.88
- 52 Week Low
- LCW $10.60
- IPHA $1.81
- 52 Week High
- LCW $11.03
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- LCW 50.58
- IPHA 50.55
- Support Level
- LCW $10.99
- IPHA $2.27
- Resistance Level
- LCW $11.01
- IPHA $2.41
- Average True Range (ATR)
- LCW 0.01
- IPHA 0.11
- MACD
- LCW -0.00
- IPHA -0.00
- Stochastic Oscillator
- LCW 50.00
- IPHA 52.94
About LCW Learn CW Investment Corporation
Learn CW Investment Corp is a blank check company. It is formed for the purpose of effecting a merger, consolidation, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.